Follicular phase treatment of luteal phase dysfunction

Area of Science:

• Reproductive Endocrinology
• Primate Models in Reproductive Research

Background:

• Selective suppression of serum follicle-stimulating hormone (FSH) using porcine follicular fluid (pFF) in early follicular phase monkeys induces luteal defects.
• These induced luteal defects resemble spontaneous luteal phase defects observed in women and monkeys.

Purpose of the Study:

• To investigate whether early FSH therapy can effectively treat luteal phase defects resulting from induced FSH deficiencies.
• To assess the impact of FSH/LH supplementation on luteal phase function following FSH suppression.

Main Methods:

• Rhesus monkeys were administered pFF to induce FSH deficiency.
• Human menopausal gonadotropin (hMG), containing FSH and luteinizing hormone (LH) in a 3:1 ratio, was administered on specific cycle days.
• Hormonal profiles (LH, FSH, estradiol) were monitored via daily radioimmunoassay of femoral blood samples.
• Ovulation and luteal phase progesterone levels were assessed.

Main Results:

• Monkeys treated with pFF and hMG exhibited a uniform single ovulation.
• Initial luteal phase serum progesterone levels in the pFF-hMG group were closer to normal ovulatory cycles compared to pFF-alone treatment.
• FSH/LH treatment partially compensated for pFF-induced endogenous FSH deficiency.

Conclusions:

• Early FSH/LH therapy can partially ameliorate luteal phase defects caused by FSH suppression.
• This study supports the role of adequate FSH levels in the early follicular phase for normal luteal function.
• Findings suggest potential therapeutic strategies for luteal phase defects involving targeted FSH administration.